Beyond AI: Three Small Caps With 10x Potential in Defense, Commodities, and Biotech

The Pattern Behind Every 10-Bagger

Before looking at individual stocks, it's worth understanding what makes a 10x return mathematically possible within 12 months.

Three conditions must be true simultaneously. The company needs to be small enough—between $1 and $10 billion market cap—because a $100 billion company has never become a trillion-dollar company in a year, but $1 billion to $10 billion has happened repeatedly. There must be a concrete event that could force the market to re-rate the stock: an FDA approval, a government contract, a profitability inflection. And institutional money must already be moving in while the broader market still ignores or dislikes the name.

Palantir followed this pattern before its 600% run. Intel, which everyone laughed at last August, is now being called the comeback story of 2026. Different sectors, different stories, same underlying setup.

Here are three names outside the AI mainstream that fit these criteria right now.

1. Big Bear AI (BBAI): Where AI Meets Defense Spending

Big Bear AI provides AI analytics for defense, national security, border security, and supply chains. They hold actual Department of Defense contracts.

What makes their positioning compelling is that they sit at the intersection of the two largest capital flows in the market right now: AI compute spending and military spending. They benefit from both simultaneously.

NATO is rearming aggressively. There's a growing pivot toward U.S.-based AI vendors for national security applications. Several new contracts are expected over the coming quarters. Last quarter's earnings growth came in at 98%.

The warnings are real, though. Margins are weak. Defense contracts tend to be sticky—once awarded, they don't change easily—but profitability remains constrained. The market cap fluctuates between roughly $1 billion and $3 billion because a very small percentage of shares are publicly traded, which creates extreme volatility.

A single bad earnings report can send this stock down 30% in one day. Size your position accordingly.

The structural setup resembles Palantir before its massive run. Is Palantir a better business? Yes. But Palantir can't 10x from its current valuation. Big Bear AI could. "Could" and "will" are very different words.

2. Compass Minerals (CMP): The Hard Asset AI Can't Touch

Salt and fertilizer. Not exactly the stuff that gets investors excited.

That's the point.

Compass Minerals operates a salt mine in Ontario and a specialty fertilizer operation (sulfate of potash) in Utah. They produce road de-icing salt, food-grade salt, and premium crop fertilizers used on fruits, vegetables, and nuts—higher-margin products than standard fertilizers.

The investment thesis here is the hard asset theme. As governments print more money and inflation erodes purchasing power, physical assets that can't be replicated gain value. AI doesn't disrupt salt. You can't 3D-print it. It's a physical resource with over a century of proven reserves.

The stock peaked at $100 and trades around $30 today. They went through a difficult debt restructuring period, but the balance sheet is cleaning up—debt-to-equity ratios are improving. Market cap is approximately $1 billion. Last quarter's earnings growth was 177%.

Catalysts:

• Rising fertilizer prices (driven partly by Middle East dynamics)
• Slightly better-than-expected recent earnings
• Institutional money beginning to flow in
• Compressed margins from temporary operational issues—normalization creates re-rating potential

This isn't a stock to bet the farm on. But it serves a valuable portfolio function: diversification away from AI risk. When everything else in your portfolio is correlated to AI spending, a physical commodity producer moves to a different beat.

3. Compass Pathways (CMPS): The 40-Year FDA Breakthrough

Compass Pathways is a mental health therapeutics company developing COMP-360, a psilocybin-based therapy.

They've completed Phase 2 clinical trials for treatment-resistant depression and are in Phase 2 for post-traumatic stress disorder. If approved, this would represent the first new FDA-approved drug class in approximately 40 years—opening a massive addressable market.

The financials are essentially blank. Zero revenue. No margins. R&D spend only. That's what makes it risky, and that's what gives it 10x potential.

The stock's price history follows the textbook innovation curve. IPO at $17 in 2020, surged to $60 during the meme stock era, crashed below $4. New innovations always follow this pattern: initial over-excitement, reality check and crash, extended quiet period, then the actual benefit proves larger than the original hype predicted.

My read is that we're at the tail end of the disappointment phase, where real value starts emerging. Last quarter's earnings growth was -59%, still negative, but improving relative to prior quarters.

This is a pure event-driven play. FDA approval could send it parabolic. Rejection could send it lower. The binary nature of the outcome is exactly why position sizing matters more here than anywhere else.

Position Sizing Is Everything

All three stocks are speculative. Speculation is fine—when it's sized like speculation.

A responsible allocation is 1-3% of your total portfolio per position. If 1% goes to zero, your portfolio barely notices. If 1% turns into 10%, it meaningfully improves your returns. That's the math of controlled speculation versus reckless gambling.

Bad earnings can crater these stocks 30% in a single session. Size accordingly. That discipline is what separates responsible investing from blind conviction.